News Home

Should You Buy Agile Therapeutics Inc (AGRX) Stock on Friday?

Friday, July 01, 2022 10:47 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Agile Therapeutics Inc (AGRX) Stock on Friday?

The market has been down on Agile Therapeutics Inc (AGRX) stock recently. AGRX gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Agile Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on AGRX!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With AGRX Stock Today?

Agile Therapeutics Inc (AGRX) stock is trading at $0.65 as of 10:47 AM on Friday, Jul 1, a loss of -$0.52, or -44.23% from the previous closing price of $1.17. The stock has traded between $0.61 and $0.71 so far today. Volume today is more active than usual. So far 32,106,148 shares have traded compared to average volume of 12,387,676 shares.

More About Agile Therapeutics Inc

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Click Here to get the full Stock Report for Agile Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App